Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM +3.61%97 EV-to-EBITDA is 27.98 as of Aug. 08, 2026, which is 32% below its 10-year median of 41.39. GuruFocus rates OCSE:CHEMM with a GF Score™ of 97/100 and a GF Value™ of kr530.04 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 512 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ChemoMetec AS's enterprise value is kr7,213.6 Mil.
ChemoMetec AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr257.9 Mil. Therefore, ChemoMetec AS's EV-to-EBITDA for today is 27.98.
The historical rank and industry rank for ChemoMetec AS's EV-to-EBITDA or its related term are showing as below:
OCSE:CHEMM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.9 Med: 41.39 Max: 149.99
Current: 27.97
During the past 13 years, the highest EV-to-EBITDA of ChemoMetec AS was 149.99. The lowest was 16.90. And the median was 41.39.
OCSE:CHEMM's EV-to-EBITDA is ranked worse than 75% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs OCSE:CHEMM: 27.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ChemoMetec AS (OCSE:CHEMM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ChemoMetec AS's PE Ratio (TTM) for today is calculated as:
ChemoMetec AS's share price for today is kr430.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr10.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ChemoMetec AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, ChemoMetec AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's EV-to-EBITDA falls into.
ChemoMetec AS's current Enterprise Value is kr7,213.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ChemoMetec AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was kr257.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChemoMetec AS (OCSE:CHEMM) has a EV-to-EBITDA of 27.98 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ChemoMetec AS. This is 32% below median its historical median of 41.39. Over the past decade, ChemoMetec AS's EV-to-EBITDA has ranged from 16.90 to 149.99. According to the industry distribution chart, ChemoMetec AS ranks #384 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 75%.
Is ChemoMetec AS's EV-to-EBITDA too high?
ChemoMetec AS's current EV-to-EBITDA of 27.98 is 32% below median its 10-year median of 41.39. Over the past 10 years, this metric has ranged from a low of 16.90 to a high of 149.99. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. ChemoMetec AS's value of 27.98 is 91.1% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #384 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #384 out of 512 companies for EV-to-EBITDA. This places ChemoMetec AS in the lower half of its industry. The industry median EV-to-EBITDA is 14.65. ChemoMetec AS's value of 27.98 is 91.1% above this benchmark. Historically, ChemoMetec AS's own EV-to-EBITDA has ranged from 16.90 to 149.99 over the past decade. While the company's 10-year median is 41.39 vs. the industry median of 14.65, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current EV-to-EBITDA of 27.98 is 91.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ChemoMetec AS. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current EV-to-EBITDA is 27.98, which is 32% below median its own 10-year median of 41.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr530.04, compared to a current price of kr430.00 — trading 18.9% below its estimated fair value. The current EV-to-EBITDA is 27.98, which is 32% below median its 10-year median of 41.39 and 91.1% above the Medical Devices & Instruments industry median of 14.65. ChemoMetec AS's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current EV-to-EBITDA is 27.98 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr430.00 is trading 18.9% below its estimated GF Value™ of kr530.04.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
EV-to-EBITDA: 27.98 (32% below median its 10-year median of 41.39)
GF Value™: kr530.04 vs. price of kr430.00 (18.9% below fair value)
Industry Position: 91.1% above the Medical Devices & Instruments median (#384 of 512)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
97GF Score
Get the complete analysis for OCSE:CHEMM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
